Financials data is unavailable for this security.
View more
Year on year Hansa Biopharma AB 's revenues fell -13.22% from 154.53m to 134.09m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 611.13m to a larger loss of 831.72m.
Gross margin | 42.86% |
---|---|
Net profit margin | -490.11% |
Operating margin | -442.93% |
Return on assets | -67.03% |
---|---|
Return on equity | -- |
Return on investment | -88.36% |
More ▼
Cash flow in SEKView more
In 2023, cash reserves at Hansa Biopharma AB fell by 764.12m. Cash Flow from Investing was negative at 284.00k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 755.65m for operations while cash used for financing totalled 7.55m.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | -3.23 |
---|---|
Tangible book value per share | -5.68 |
More ▼
Balance sheet in SEKView more
Current ratio | 3.05 |
---|---|
Quick ratio | 3.04 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 1.29 |
More ▼